We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Platelet response to increased aspirin dose in patients with persistent platelet aggregation while treated with aspirin 81 mg.
- Authors
Gengo, Fran; Westphal, Erica S.; Rainka, Michelle M.; Janda, Maria; Robson, Matthew J.; Hourihane, J. Maurice; Bates, Vernice
- Abstract
This study demonstrates that patients who are taking 81 mg of aspirin and are nonresponsive benefit from a dose of 162 mg or greater vs a different antiplatelet therapy. We identified 100 patients who were nonresponsive to aspirin 81 mg via whole blood aggregometry and observed how many patients became responsive at a dose of 162 mg or greater. Platelet nonresponsiveness was defined as >10 Ω of resistance to collagen 1 µg/mL and/or an ohms ratio of collagen 1 µg/mL to collagen 5 µg/mL >0.5 and/or >6 Ω to arachidonate. Borderline response was defined as an improvement in 1 but not both of the above criteria. Of the initial 100 patients who were nonresponsive to an aspirin dose of 81 mg, 79% became responsive at a dose of 162 mg or >162 mg. Only 6% did not respond to any increase in dose. We believe that patients treated with low-dose aspirin who have significant risk for secondary vascular events should be individually assessed to determine their antiplatelet response. Those found to have persistent platelet aggregation despite treatment with 81 mg of aspirin have a higher likelihood of obtaining an adequate antiplatelet response at a higher aspirin dose.
- Subjects
NEW York (State); CARDIOVASCULAR disease prevention; ASPIRIN; BLOOD platelet aggregation; CARDIOVASCULAR diseases; PATIENTS; PROBABILITY theory; RESEARCH funding; STROKE; DATA analysis; RETROSPECTIVE studies; DATA analysis software; PLATELET aggregation inhibitors; DESCRIPTIVE statistics; KRUSKAL-Wallis Test; THERAPEUTICS
- Publication
Journal of Clinical Pharmacology, 2016, Vol 56, Issue 4, p414
- ISSN
0091-2700
- Publication type
Article
- DOI
10.1002/jcph.608